- GSK and Janssen wade into competitive RA market with Phase III sirukumab program
- Abbott's Humira gets eighth indication approval in the EU
- UCB seeks new indications for Cimzia in US, EU
- Device sets $5000 a year cost challenge for RA anti-TNF drugs
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.